Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MELRN)
| ADC Name |
BC2027
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BC2027
Click to Show/Hide
|
|||||
| Organization |
BioCity Biopharmaceutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-GPC3 antibody
|
Antibody Info | ||||
| Antigen Name |
Glypican-3 (GPC3)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Sarcoma |
1 Trials
|
|||||
| Oesophageal cancer |
1 Trials
|
|||||
| Liver cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|